Protein Official symbol | MMP2 |
Aliases | MMP2 CLG4A |
Chromosomal Location | 16 |
Length | 660 |
Uniprot ID | P08253 |
EC number | 3.4.24.24 |
Protein family Information(Pfam) | PF00040;PF00045;PF00413;PF01471; |
PDB id | 1CK7;1CXW;1EAK;1GEN;1GXD;1HOV;1J7M;1KS0;1QIB;1RTG;3AYU; |
InterPro ID | IPR028708;IPR000562;IPR036943;IPR000585;IPR036375;IPR018487;IPR018486;IPR013806;IPR033739;IPR024079;IPR001818;IPR021190;IPR021158;IPR006026;IPR002477;IPR036365;IPR036366; |
dbSNP | rs121912953 rs759302357 rs121912955 rs17859943 rs764961297 rs16955280 |
Protein 1 | Protein 2 | Combine Score |
---|---|---|
TIMP2 | MMP2 | 0.999 |
SRC | STAT3 | 0.995 |
VEGFA | STAT3 | 0.994 |
MMP2 | DCN | 0.993 |
VEGFA | SRC | 0.987 |
COL18A1 | MMP2 | 0.985 |
TIMP3 | MMP2 | 0.985 |
VEGFA | MMP2 | 0.979 |
STAT3 | MMP2 | 0.979 |
MMP2 | TIMP1 | 0.976 |
SRC | MMP2 | 0.974 |
VEGFA | TIMP1 | 0.973 |
ACAN | MMP2 | 0.972 |
STAT3 | TIMP1 | 0.971 |
COL1A1 | MMP2 | 0.97 |
COL1A1 | DCN | 0.966 |
COL18A1 | COL1A1 | 0.926 |
VEGFA | COL18A1 | 0.884 |
ACAN | DCN | 0.86 |
TIMP3 | TIMP2 | 0.762 |
VEGFA | DCN | 0.759 |
ACAN | COL1A1 | 0.744 |
COL1A1 | TIMP1 | 0.713 |
VEGFA | TIMP2 | 0.676 |
ACAN | TIMP1 | 0.672 |
ACAN | TIMP3 | 0.645 |
TIMP3 | COL1A1 | 0.628 |
VEGFA | TIMP3 | 0.603 |
TIMP3 | DCN | 0.588 |
TIMP1 | DCN | 0.586 |
TIMP2 | COL1A1 | 0.582 |
COL18A1 | TIMP1 | 0.569 |
ACAN | TIMP2 | 0.552 |
VEGFA | ACAN | 0.54 |
TIMP2 | DCN | 0.526 |
VEGFA | COL1A1 | 0.518 |
COL18A1 | TIMP2 | 0.504 |
COL18A1 | TIMP3 | 0.468 |
COL18A1 | DCN | 0.455 |
# | 7077 (TIMP2) | 6714 (SRC) | 7422 (VEGFA) | 4313 (MMP2) | 80781 (COL18A1) | 7078 (TIMP3) | 6774 (STAT3) | 176 (ACAN) | 1277 (COL1A1) | 7076 (TIMP1) | 1634 (DCN) |
---|---|---|---|---|---|---|---|---|---|---|---|
7077 (TIMP2) | 1.00 | 0.56 | 0.57 | 0.41 | 0.19 | 0.87 | 0.46 | 0.47 | 0.60 | 0.97 | 0.48 |
6714 (SRC) | 0.56 | 1.00 | 0.64 | 0.55 | 0.18 | 0.58 | 0.55 | 0.56 | 0.59 | 0.57 | 0.58 |
7422 (VEGFA) | 0.57 | 0.64 | 1.00 | 0.56 | 0.20 | 0.60 | 0.58 | 0.59 | 0.63 | 0.61 | 0.59 |
4313 (MMP2) | 0.41 | 0.55 | 0.56 | 1.00 | 0.19 | 0.46 | 0.44 | 0.41 | 0.51 | 0.44 | 0.43 |
80781 (COL18A1) | 0.19 | 0.18 | 0.20 | 0.19 | 1.00 | 0.20 | 0.18 | 0.78 | 0.61 | 0.19 | 0.54 |
7078 (TIMP3) | 0.87 | 0.58 | 0.60 | 0.46 | 0.20 | 1.00 | 0.48 | 0.55 | 0.68 | 0.85 | 0.56 |
6774 (STAT3) | 0.46 | 0.55 | 0.58 | 0.44 | 0.18 | 0.48 | 1.00 | 0.47 | 0.52 | 0.47 | 0.54 |
176 (ACAN) | 0.47 | 0.56 | 0.59 | 0.41 | 0.78 | 0.55 | 0.47 | 1.00 | 0.87 | 0.49 | 0.86 |
1277 (COL1A1) | 0.60 | 0.59 | 0.63 | 0.51 | 0.61 | 0.68 | 0.52 | 0.87 | 1.00 | 0.60 | 0.76 |
7076 (TIMP1) | 0.97 | 0.57 | 0.61 | 0.44 | 0.19 | 0.85 | 0.47 | 0.49 | 0.60 | 1.00 | 0.51 |
1634 (DCN) | 0.48 | 0.58 | 0.59 | 0.43 | 0.54 | 0.56 | 0.54 | 0.86 | 0.76 | 0.51 | 1.00 |
Protein Official symbol | Source Organism | Tissue of Expression | Level of hypoxia | Altitude | Duration of experiment | Level of expression | Fold change | Experiment details | geographical location | ethnicity of the patients | Control group | Control (Fold change) | Reference (PMID) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MMP2 | Toad | Liver | - | 3464 m | 33 day | downregulated | -2.153712659 | RNA-seq | Tibetan Plateau | Asiatic toad | 1 | Zoige (High altitute Toad) Vs Chengdu (Low altitude toad) - | 28673260 |
TF | TF Entrez | Gene | Gene Entrez | Type | PMID | Database |
---|---|---|---|---|---|---|
CEBPE | 1053 | MMP2 | 4313 | Activation | 17487558 | TRUSST |
EZH2 | 2146 | MMP2 | 4313 | Unknown | 8670251 | TRUSST |
ATF2 | 1386 | MMP2 | 4313 | Unknown | 14610084 | TRUSST |
ETV5 | 2119 | MMP2 | 4313 | Unknown | 12855590 | TRUSST |
HDAC3 | 8841 | MMP2 | 4313 | Activation | 9295016 | TRUSST |
CREB1 | 1385 | MMP2 | 4313 | Activation | 17487558 | TRUSST |
MZF1 | 7593 | MMP2 | 4313 | Repression | 23319049 | TRUSST |
HOXB7 | 3217 | MMP2 | 4313 | Unknown | 11556732 | TRUSST |
NFKB1 | 4790 | MMP2 | 4313 | Unknown | 20729552 | TRUSST |
ETS2 | 2114 | MMP2 | 4313 | Activation | 15235127 | TRUSST |
KLF4 | 9314 | MMP2 | 4313 | Unknown | 14610084 | TRUSST |
MSC | 9242 | MMP2 | 4313 | Repression | 23319049 | TRUSST |
ETV4 | 2118 | MMP2 | 4313 | Activation | 22632819 | TRUSST |
HTATIP2 | 10553 | MMP2 | 4313 | Repression | 23319049 | TRUSST |
JUN | 3725 | MMP2 | 4313 | Unknown | 11875117 | TRUSST |
ATF3 | 467 | MMP2 | 4313 | Unknown | 10954416 | TRUSST |
HIF1A | 3091 | MMP2 | 4313 | Unknown | 8670251 | TRUSST |
SSX2 | 6757 | MMP2 | 4313 | Unknown | 10816578 | TRUSST |
TP53 | 7157 | MMP2 | 4313 | Unknown | 8550612 | TRUSST |
SP1 | 6667 | MMP2 | 4313 | Unknown | 10816578 | TRUSST |
PAX6 | 5080 | MMP2 | 4313 | Unknown | 21878622 | TRUSST |
RUNX2 | 860 | MMP2 | 4313 | Unknown | 10816578 | TRUSST |
TFAP2C | 7022 | MMP2 | 4313 | Repression | 10585866 | TRUSST |
NR4A1 | 3164 | MMP2 | 4313 | Activation | 17490615 | TRUSST |
SP3 | 6670 | MMP2 | 4313 | Activation | 11435435 | TRUSST |
TFAP2A | 7020 | MMP2 | 4313 | Unknown | 15191537 | TRUSST |
TWIST1 | 7291 | MMP2 | 4313 | Unknown | 11163768 | TRUSST |
STAT3 | 6774 | MMP2 | 4313 | Unknown | 23599428 | TRUSST |
RELA | 5970 | MMP2 | 4313 | Unknown | 21878622 | TRUSST |
SRF | 6722 | MMP2 | 4313 | Unknown | 15790882 | TRUSST |
YBX1 | 4904 | MMP2 | 4313 | Unknown | 19876927 | TRUSST |
TWIST2 | 117581 | MMP2 | 4313 | Unknown | 11163768 | TRUSST |
miRTarBase ID | miRNA | Species (miRNA) | Protein Official Symbol | Human Entrez ID | Species (Target Gene) | Experiments | Support Type | References (PMID) |
---|---|---|---|---|---|---|---|---|
MIRT005570 | hsa-miR-29b-3p | Homo sapiens | MMP2 | 4313 | Homo sapiens | Microarray | Functional MTI (Weak) | 22942087 |
MIRT005570 | hsa-miR-29b-3p | Homo sapiens | MMP2 | 4313 | Homo sapiens | Luciferase reporter assay//qRT-PCR//Western blot | Functional MTI | 20657750 |
MIRT005570 | hsa-miR-29b-3p | Homo sapiens | MMP2 | 4313 | Homo sapiens | Luciferase reporter assay | Functional MTI | 22745231 |
MIRT005570 | hsa-miR-29b-3p | Homo sapiens | MMP2 | 4313 | Homo sapiens | Western blot | Functional MTI | 24130681 |
MIRT005570 | hsa-miR-29b-3p | Homo sapiens | MMP2 | 4313 | Homo sapiens | Luciferase reporter assay//qRT-PCR | Functional MTI | 23354167 |
MIRT005570 | hsa-miR-29b-3p | Homo sapiens | MMP2 | 4313 | Homo sapiens | Luciferase reporter assay//qRT-PCR//Western blot | Functional MTI | 26063204 |
MIRT005570 | hsa-miR-29b-3p | Homo sapiens | MMP2 | 4313 | Homo sapiens | Immunofluorescence//Immunohistochemistry//Luciferase reporter assay//Northern blot//qRT-PCR//Western blot | Functional MTI | 24130168 |
MIRT005570 | hsa-miR-29b-3p | Homo sapiens | MMP2 | 4313 | Homo sapiens | Western blot | Functional MTI | 23254643 |
MIRT005570 | hsa-miR-29b-3p | Homo sapiens | MMP2 | 4313 | Homo sapiens | Western blot | Functional MTI | 24147037 |
MIRT005742 | hsa-miR-451a | Homo sapiens | MMP2 | 4313 | Homo sapiens | qRT-PCR//Western blot | Functional MTI | 20816946 |
MIRT005742 | hsa-miR-451a | Homo sapiens | MMP2 | 4313 | Homo sapiens | qRT-PCR//Western blot | Functional MTI | 27173190 |
MIRT018099 | hsa-miR-335-5p | Homo sapiens | MMP2 | 4313 | Homo sapiens | Microarray | Functional MTI (Weak) | 18185580 |
MIRT019228 | hsa-miR-338-3p | Homo sapiens | MMP2 | 4313 | Homo sapiens | Western blot;qRT-PCR | Non-Functional MTI | 21671467 |
MIRT030716 | hsa-miR-21-5p | Homo sapiens | MMP2 | 4313 | Homo sapiens | qRT-PCR | Functional MTI (Weak) | 19435867 |
MIRT031370 | hsa-miR-17-5p | Homo sapiens | MMP2 | 4313 | Homo sapiens | Western blot | Functional MTI | 20209605 |
MIRT053245 | hsa-miR-29c-3p | Homo sapiens | MMP2 | 4313 | Homo sapiens | Immunofluorescence//Immunohistochemistry//Luciferase reporter assay//Northern blot//qRT-PCR//Western blot | Functional MTI | 24130168 |
MIRT053245 | hsa-miR-29c-3p | Homo sapiens | MMP2 | 4313 | Homo sapiens | Luciferase reporter assay//qRT-PCR//Western blot | Functional MTI | 23936390 |
MIRT053481 | hsa-miR-9-5p | Homo sapiens | MMP2 | 4313 | Homo sapiens | qRT-PCR | Functional MTI (Weak) | 21931274 |
MIRT053245 | hsa-miR-29c-3p | Homo sapiens | MMP2 | 4313 | Homo sapiens | Luciferase reporter assay | Functional MTI | 22745231 |
MIRT053580 | hsa-miR-29a-3p | Homo sapiens | MMP2 | 4313 | Homo sapiens | Luciferase reporter assay | Functional MTI | 22745231 |
MIRT053245 | hsa-miR-29c-3p | Homo sapiens | MMP2 | 4313 | Homo sapiens | qRT-PCR//Western blot | Functional MTI | 23175151 |
MIRT053336 | hsa-miR-491-5p | Homo sapiens | MMP2 | 4313 | Homo sapiens | Immunohistochemistry//Microarray//qRT-PCR//Western blot | Functional MTI | 23725476 |
MIRT053580 | hsa-miR-29a-3p | Homo sapiens | MMP2 | 4313 | Homo sapiens | Luciferase reporter assay | Functional MTI | 26700017 |
MIRT053580 | hsa-miR-29a-3p | Homo sapiens | MMP2 | 4313 | Homo sapiens | Immunofluorescence//Immunohistochemistry//Luciferase reporter assay//Northern blot//qRT-PCR//Western blot | Functional MTI | 24130168 |
MIRT053580 | hsa-miR-29a-3p | Homo sapiens | MMP2 | 4313 | Homo sapiens | Flow//Luciferase reporter assay//qRT-PCR//Western blot | Functional MTI | 24210072 |
MIRT053787 | hsa-miR-452-5p | Homo sapiens | MMP2 | 4313 | Homo sapiens | Microarray//qRT-PCR | Functional MTI (Weak) | 22952876 |
MIRT437388 | hsa-miR-708-5p | Homo sapiens | MMP2 | 4313 | Homo sapiens | Flow//qRT-PCR//Western blot | Functional MTI | 23754151 |
MIRT437572 | hsa-miR-767-5p | Homo sapiens | MMP2 | 4313 | Homo sapiens | Luciferase reporter assay | Functional MTI | 22745231 |
MIRT438153 | hsa-miR-106b-5p | Homo sapiens | MMP2 | 4313 | Homo sapiens | Luciferase reporter assay | Functional MTI | 24164962 |
MIRT438234 | hsa-miR-221-3p | Homo sapiens | MMP2 | 4313 | Homo sapiens | Western blot | Functional MTI | 24147037 |
MIRT440222 | hsa-miR-544a | Homo sapiens | MMP2 | 4313 | Homo sapiens | HITS-CLIP | Functional MTI (Weak) | 24374217 |
MIRT724935 | hsa-miR-29b-2-5p | Homo sapiens | MMP2 | 4313 | Homo sapiens | HITS-CLIP | Functional MTI (Weak) | 19536157 |
MIRT724933 | hsa-miR-1238-3p | Homo sapiens | MMP2 | 4313 | Homo sapiens | HITS-CLIP | Functional MTI (Weak) | 19536157 |
MIRT724934 | hsa-miR-670-3p | Homo sapiens | MMP2 | 4313 | Homo sapiens | HITS-CLIP | Functional MTI (Weak) | 19536157 |
MIRT724937 | hsa-miR-6792-3p | Homo sapiens | MMP2 | 4313 | Homo sapiens | HITS-CLIP | Functional MTI (Weak) | 19536157 |
MIRT724936 | hsa-miR-6749-3p | Homo sapiens | MMP2 | 4313 | Homo sapiens | HITS-CLIP | Functional MTI (Weak) | 19536157 |
MIRT724938 | hsa-miR-4691-5p | Homo sapiens | MMP2 | 4313 | Homo sapiens | HITS-CLIP | Functional MTI (Weak) | 19536157 |
MIRT731453 | hsa-miR-125b-5p | Homo sapiens | MMP2 | 4313 | Homo sapiens | Luciferase reporter assay | Functional MTI | 27133077 |
MIRT731061 | hsa-miR-130b-3p | Homo sapiens | MMP2 | 4313 | Homo sapiens | qRT-PCR//Luciferase reporter assay//Western blot | Functional MTI | 25154741 |
MIRT732848 | hsa-miR-520g-3p | Homo sapiens | MMP2 | 4313 | Homo sapiens | In situ hybridization//Luciferase reporter assay//qRT-PCR//Western blot | Functional MTI | 28292471 |
MIRT733143 | hsa-miR-524-5p | Homo sapiens | MMP2 | 4313 | Homo sapiens | qRT-PCR//Western blot | Functional MTI | 26998102 |
MIRT733418 | hsa-miR-302a-5p | Homo sapiens | MMP2 | 4313 | Homo sapiens | ELISA//Western blot | Functional MTI | 26191138 |
MIRT734261 | hsa-miR-218-5p | Homo sapiens | MMP2 | 4313 | Homo sapiens | qRT-PCR//Western blot | Functional MTI | 26133092 |
MIRT734404 | hsa-miR-203a-5p | Homo sapiens | MMP2 | 4313 | Homo sapiens | Western blot | Functional MTI | 26278219 |
MIRT734784 | hsa-miR-143-3p | Homo sapiens | MMP2 | 4313 | Homo sapiens | qRT-PCR//Western blot | Functional MTI | 26722463 |
MIRT734996 | hsa-miR-519d-3p | Homo sapiens | MMP2 | 4313 | Homo sapiens | Luciferase reporter assay | Functional MTI | 25803859 |
ID | GO ID | GO Term | GO Type |
---|---|---|---|
4313 | GO:0001525 | angiogenesis | GOTERM_BP_DIRECT |
4313 | GO:0001666 | response to hypoxia | GOTERM_BP_DIRECT |
4313 | GO:0044267 | cellular protein metabolic process | GOTERM_BP_DIRECT |
4313 | GO:0005739 | mitochondrion | GOTERM_CC_DIRECT |
4313 | GO:0001955 | blood vessel maturation | GOTERM_BP_DIRECT |
4313 | GO:0004252 | serine-type endopeptidase activity | GOTERM_MF_DIRECT |
4313 | GO:0005886 | plasma membrane | GOTERM_CC_DIRECT |
4313 | GO:0048013 | ephrin receptor signaling pathway | GOTERM_BP_DIRECT |
4313 | GO:0030017 | sarcomere | GOTERM_CC_DIRECT |
4313 | GO:0030574 | collagen catabolic process | GOTERM_BP_DIRECT |
4313 | GO:0045089 | positive regulation of innate immune response | GOTERM_BP_DIRECT |
4313 | GO:0005634 | nucleus | GOTERM_CC_DIRECT |
4313 | GO:0060346 | bone trabecula formation | GOTERM_BP_DIRECT |
4313 | GO:0031012 | extracellular matrix | GOTERM_CC_DIRECT |
4313 | GO:0007566 | embryo implantation | GOTERM_BP_DIRECT |
4313 | GO:0001957 | intramembranous ossification | GOTERM_BP_DIRECT |
4313 | GO:0005576 | extracellular region | GOTERM_CC_DIRECT |
4313 | GO:0005578 | proteinaceous extracellular matrix | GOTERM_CC_DIRECT |
4313 | GO:1904707 | positive regulation of vascular smooth muscle cell proliferation | GOTERM_BP_DIRECT |
4313 | GO:0004222 | cysteine-type endopeptidase activity | GOTERM_MF_DIRECT |
4313 | GO:0022617 | extracellular matrix disassembly | GOTERM_BP_DIRECT |
4313 | GO:0005615 | extracellular space | GOTERM_CC_DIRECT |
4313 | GO:0071230 | cellular response to amino acid stimulus | GOTERM_BP_DIRECT |
4313 | GO:0005515 | protein binding | GOTERM_MF_DIRECT |
4313 | GO:0008270 | zinc ion binding | GOTERM_MF_DIRECT |
4313 | GO:0006508 | proteolysis | GOTERM_BP_DIRECT |
4313 | GO:0060325 | face morphogenesis | GOTERM_BP_DIRECT |
4313 | GO:0035987 | endodermal cell differentiation | GOTERM_BP_DIRECT |
4313 | GO:0008237 | metallopeptidase activity | GOTERM_MF_DIRECT |
Protein Official Symbol | Human Entrez ID | Disease Name | Disease Id | Disease Semantic Type | Semantic score | DSI | DPI | Disease Type |
---|---|---|---|---|---|---|---|---|
MMP2 | 4313 | Nose Neoplasms | C0028433 | Neoplastic Process | 0.3 | 0.373 | 0.862 | group |
MMP2 | 4313 | Aortic Aneurysm, Thoracic | C0162872 | Disease or Syndrome | 0.54 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Malignant Bone Neoplasm | C0279530 | Neoplastic Process | 0.3 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Testicular Germ Cell Tumor | C1336708 | Neoplastic Process | 0.3 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Glioblastoma Multiforme | C1621958 | Neoplastic Process | 0.35 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Liver Cirrhosis, Alcoholic | C0023891 | Disease or Syndrome | 0.3 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Neoplasm Invasiveness | C0027626 | Pathologic Function | 0.3 | 0.373 | 0.862 | phenotype |
MMP2 | 4313 | Neoplasm Metastasis | C0027627 | Neoplastic Process | 0.4 | 0.373 | 0.862 | phenotype |
MMP2 | 4313 | Neointima Formation | C2936381 | Pathologic Function | 0.3 | 0.373 | 0.862 | phenotype |
MMP2 | 4313 | Drug-Induced Acute Liver Injury | C3658290 | Disease or Syndrome | 0.3 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Rheumatoid Arthritis | C0003873 | Disease or Syndrome | 0.4 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Malignant neoplasm of breast | C0006142 | Neoplastic Process | 0.4 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Colorectal Neoplasms | C0009404 | Neoplastic Process | 0.4 | 0.373 | 0.862 | group |
MMP2 | 4313 | Diabetic Neuropathies | C0011882 | Disease or Syndrome | 0.3 | 0.373 | 0.862 | group |
MMP2 | 4313 | Glioblastoma | C0017636 | Neoplastic Process | 0.4 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Maxillary Diseases | C0024950 | Disease or Syndrome | 0.3 | 0.373 | 0.862 | group |
MMP2 | 4313 | Diabetic Asymmetric Polyneuropathy | C0393835 | Disease or Syndrome | 0.3 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Aortic Diseases | C0003493 | Disease or Syndrome | 0.3 | 0.373 | 0.862 | group |
MMP2 | 4313 | Aortic Rupture | C0003496 | Disease or Syndrome | 0.31 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Colorectal Carcinoma | C0009402 | Neoplastic Process | 0.4 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Inflammation | C0021368 | Pathologic Function | 0.31 | 0.373 | 0.862 | phenotype |
MMP2 | 4313 | Diabetic Mononeuropathy | C0271678 | Disease or Syndrome | 0.3 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Diabetic Autonomic Neuropathy | C0271686 | Disease or Syndrome | 0.3 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Craniofacial Abnormalities | C0376634 | Congenital Abnormality | 0.3 | 0.373 | 0.862 | group |
MMP2 | 4313 | Aseptic Necrosis of Bone | C0520474 | Pathologic Function | 0.3 | 0.373 | 0.862 | phenotype |
MMP2 | 4313 | Lupus Nephritis | C0024143 | Disease or Syndrome | 0.3 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Mandibular Diseases | C0024689 | Disease or Syndrome | 0.3 | 0.373 | 0.862 | group |
MMP2 | 4313 | Cholestasis, Extrahepatic | C0005398 | Disease or Syndrome | 0.3 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Bone Diseases | C0005940 | Disease or Syndrome | 0.31 | 0.373 | 0.862 | group |
MMP2 | 4313 | Hepatitis, Toxic | C0019193 | Injury or Poisoning | 0.3 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Weight Gain | C0043094 | Finding | 0.3 | 0.373 | 0.862 | phenotype |
MMP2 | 4313 | Urban cutaneous leishmaniasis | C0086541 | Disease or Syndrome | 0.3 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Panacinar Emphysema | C0264393 | Disease or Syndrome | 0.3 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Liver carcinoma | C2239176 | Neoplastic Process | 0.4 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Osteosarcoma | C0029463 | Neoplastic Process | 0.4 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Hamman-Rich syndrome | C0085786 | Disease or Syndrome | 0.3 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Centriacinar Emphysema | C0221227 | Disease or Syndrome | 0.3 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Fibrosis, Liver | C0239946 | Disease or Syndrome | 0.37 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Tumoral calcinosis | C0263628 | Disease or Syndrome | 0.3 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Diabetic Polyneuropathies | C0271680 | Disease or Syndrome | 0.3 | 0.373 | 0.862 | group |
MMP2 | 4313 | Cancer of Nose | C0751394 | Neoplastic Process | 0.3 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Alloxan Diabetes | C0002152 | Experimental Model of Disease | 0.3 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Calcinosis | C0006663 | Pathologic Function | 0.3 | 0.373 | 0.862 | phenotype |
MMP2 | 4313 | Liver Cirrhosis | C0023890 | Disease or Syndrome | 0.5 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Marfan Syndrome | C0024796 | Disease or Syndrome | 0.31 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Myocardial Infarction | C0027051 | Disease or Syndrome | 0.53 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Nasopharyngeal Neoplasms | C0027439 | Neoplastic Process | 0.3 | 0.373 | 0.862 | group |
MMP2 | 4313 | Cancer of Nasopharynx | C0238301 | Neoplastic Process | 0.31 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Chemical and Drug Induced Liver Injury | C4277682 | Disease or Syndrome | 0.3 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Metabolic Bone Disorder | C0005944 | Disease or Syndrome | 0.3 | 0.373 | 0.862 | group |
MMP2 | 4313 | Diabetes Mellitus, Experimental | C0011853 | Experimental Model of Disease | 0.3 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Liver Cirrhosis, Experimental | C0023893 | Experimental Model of Disease | 0.3 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Disease Exacerbation | C0235874 | Finding | 0.3 | 0.373 | 0.862 | phenotype |
MMP2 | 4313 | Neointima | C2936380 | Acquired Abnormality | 0.3 | 0.373 | 0.862 | phenotype |
MMP2 | 4313 | Hypertensive disease | C0020538 | Disease or Syndrome | 0.6 | 0.373 | 0.862 | group |
MMP2 | 4313 | Bone necrosis | C0029445 | Pathologic Function | 0.3 | 0.373 | 0.862 | phenotype |
MMP2 | 4313 | Streptozotocin Diabetes | C0038433 | Experimental Model of Disease | 0.3 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Breast Carcinoma | C0678222 | Neoplastic Process | 0.4 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Diabetic Neuralgia | C0751074 | Disease or Syndrome | 0.3 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Drug-Induced Liver Disease | C0860207 | Disease or Syndrome | 0.3 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Chemically-Induced Liver Toxicity | C4279912 | Disease or Syndrome | 0.3 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Oral Submucous Fibrosis | C0029172 | Disease or Syndrome | 0.31 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Osteopenia | C0029453 | Disease or Syndrome | 0.42 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Focal Emphysema | C2350878 | Disease or Syndrome | 0.3 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Fetal Growth Retardation | C0015934 | Pathologic Function | 0.31 | 0.373 | 0.862 | phenotype |
MMP2 | 4313 | Avascular necrosis of bone | C0027543 | Pathologic Function | 0.3 | 0.373 | 0.862 | phenotype |
MMP2 | 4313 | Pulmonary Emphysema | C0034067 | Disease or Syndrome | 0.33 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Pulmonary Fibrosis | C0034069 | Disease or Syndrome | 0.32 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Leishmaniasis, New World | C0086540 | Disease or Syndrome | 0.3 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Diabetic Amyotrophy | C0271685 | Disease or Syndrome | 0.3 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Symmetric Diabetic Proximal Motor Neuropathy | C0271673 | Disease or Syndrome | 0.3 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Giant Cell Glioblastoma | C0334588 | Neoplastic Process | 0.3 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Hepatitis, Drug-Induced | C1262760 | Disease or Syndrome | 0.3 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Mammary Neoplasms | C1458155 | Neoplastic Process | 0.4 | 0.373 | 0.862 | group |
MMP2 | 4313 | Cerebral Hemorrhage | C2937358 | Pathologic Function | 0.3 | 0.373 | 0.862 | phenotype |
MMP2 | 4313 | Bone neoplasms | C0005967 | Neoplastic Process | 0.3 | 0.373 | 0.862 | group |
MMP2 | 4313 | Kienbock Disease | C0022682 | Disease or Syndrome | 0.3 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Leishmaniasis, Cutaneous | C0023283 | Disease or Syndrome | 0.3 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Asymmetric Diabetic Proximal Motor Neuropathy | C0271674 | Disease or Syndrome | 0.3 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Aortic Aneurysm, Thoracoabdominal | C0340630 | Disease or Syndrome | 0.3 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Microcalcification | C0521174 | Pathologic Function | 0.3 | 0.373 | 0.862 | phenotype |
MMP2 | 4313 | Aortic Aneurysm, Ruptured | C0741160 | Disease or Syndrome | 0.3 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Mammary Neoplasms, Human | C1257931 | Neoplastic Process | 0.3 | 0.373 | 0.862 | group |
MMP2 | 4313 | Nasopharyngeal carcinoma | C2931822 | Neoplastic Process | 0.4 | 0.373 | 0.862 | disease |
MMP2 | 4313 | TORG-WINCHESTER SYNDROME | C1850155 | Disease or Syndrome | 0.78 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Colorectal Cancer | C1527249 | Neoplastic Process | 0.7 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Alcoholic Intoxication, Chronic | C0001973 | Mental or Behavioral Dysfunction | 0.3 | 0.373 | 0.862 | disease |
MMP2 | 4313 | Alcohol abuse | C0085762 | Mental or Behavioral Dysfunction | 0.51 | 0.373 | 0.862 | disease |
Protein Official Symbol | Human Entrez ID | drug_claim_primary_name | drug_name | drug_chembl_id | interaction_types |
---|---|---|---|---|---|
MMP2 | 4313 | 4-HYDROPEROXYCYCLOPHOSPHAMIDE | PERFOSFAMIDE | CHEMBL61511 | None |
MMP2 | 4313 | AE-941 | None | None | None |
MMP2 | 4313 | ARP100 | CHEMBL181244 | CHEMBL181244 | inhibitor |
MMP2 | 4313 | BATIMASTAT | BATIMASTAT | CHEMBL279786 | inhibitor |
MMP2 | 4313 | AZD6605 | None | None | inhibitor |
MMP2 | 4313 | BB-3644 | SOLIMASTAT | CHEMBL2107228 | inhibitor |
MMP2 | 4313 | BEVACIZUMAB | BEVACIZUMAB | CHEMBL1201583 | None |
MMP2 | 4313 | BMS-275291 | REBIMASTAT | CHEMBL76222 | None |
MMP2 | 4313 | BMS 275291 | REBIMASTAT | CHEMBL76222 | inhibitor |
MMP2 | 4313 | CGS-27023A | CGS-27023A | CHEMBL514138 | inhibitor |
MMP2 | 4313 | CHLORHEXIDINE | CHLORHEXIDINE | CHEMBL790 | None |
MMP2 | 4313 | CHONDROITIN | CHONDROITIN SULFATE | CHEMBL2303614 | None |
MMP2 | 4313 | COL-3 | INCYCLINIDE | CHEMBL2104970 | None |
MMP2 | 4313 | CSA | CYCLOSPORINE | CHEMBL160 | None |
MMP2 | 4313 | G-CSF | FILGRASTIM | CHEMBL1201567 | None |
MMP2 | 4313 | HEPARAN SULFATE | None | None | None |
MMP2 | 4313 | ILOMASTAT | ILOMASTAT | CHEMBL19611 | inhibitor |
MMP2 | 4313 | IL-2 | None | None | None |
MMP2 | 4313 | IMMUNOSUPPRESSIVE | None | None | None |
MMP2 | 4313 | LETROZOLE | LETROZOLE | CHEMBL1444 | None |
MMP2 | 4313 | MARIMASTAT | MARIMASTAT | CHEMBL279785 | None |
MMP2 | 4313 | MARIMASTAT | MARIMASTAT | CHEMBL279785 | None |
MMP2 | 4313 | MARIMASTAT | MARIMASTAT | CHEMBL279785 | inhibitor |
MMP2 | 4313 | METASTAT | INCYCLINIDE | CHEMBL2104970 | inhibitor |
MMP2 | 4313 | MUSTARD | None | None | None |
MMP2 | 4313 | NEOVASTAT | None | None | inhibitor |
MMP2 | 4313 | PACLITAXEL | PACLITAXEL | CHEMBL428647 | None |
MMP2 | 4313 | PG-116800 | None | None | inhibitor |
MMP2 | 4313 | PRINOMASTAT | PRINOMASTAT | CHEMBL75094 | inhibitor |
MMP2 | 4313 | POLYPHENOL | None | None | None |
MMP2 | 4313 | PRINOMASTAT | PRINOMASTAT | CHEMBL75094 | vaccine |
MMP2 | 4313 | PRAVASTATIN | PRAVASTATIN | CHEMBL1144 | None |
MMP2 | 4313 | RAMIPRIL | RAMIPRIL | CHEMBL1168 | None |
MMP2 | 4313 | RESVERATROL | RESVERATROL | CHEMBL165 | None |
MMP2 | 4313 | RETINOID | ETRETINATE | CHEMBL464 | None |
MMP2 | 4313 | S-3304 | None | None | vaccine |
MMP2 | 4313 | RO-26-2853 | None | None | inhibitor |
MMP2 | 4313 | SB-3CT | None | None | inhibitor |
MMP2 | 4313 | SIMVASTATIN | SIMVASTATIN | CHEMBL1064 | None |
MMP2 | 4313 | SERMS | None | None | None |
MMP2 | 4313 | STREPTOZOTOCIN | STREPTOZOTOCIN | CHEMBL1651906 | None |
MMP2 | 4313 | TANOMASTAT | TANOMASTAT | CHEMBL261932 | inhibitor |
MMP2 | 4313 | TANOMASTAT | TANOMASTAT | CHEMBL261932 | inhibitor |
MMP2 | 4313 | TILUDRONIC ACID | TILUDRONIC ACID | CHEMBL1350 | inhibitor |
MMP2 | 4313 | TST10088 | None | None | None |
MMP2 | 4313 | VINBLASTINE | VINBLASTINE | CHEMBL159 | None |